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Microarray analysis offers a powerful tool for studying the mechanisms of cellular transformation, although the correlation between
mRNA and protein expression is largely unknown. In this study, a microarray analysis was performed to compare transcription in
response to overexpression of the ErbB-2 receptor tyrosine kinase in a model mammary luminal epithelial cell system, and in
response to the ErbB-specific growth factor heregulin b1. We sought to validate mRNA changes by monitoring changes at the
protein level using a parallel proteomics strategy, and report a surprisingly high correlation between transcription and translation for
the subset of genes studied. We further characterised the identified targets and relate differential expression to changes in the
biological properties of ErbB-2-overexpressing cells. We found differential regulation of several key cell cycle modulators, including
cyclin D2, and downregulation of a large number of interferon-inducible genes, consistent with increased proliferation of the ErbB-2-
overexpressing cells. Furthermore, differential expression of genes involved in extracellular matrix modelling and cellular adhesion was
linked to altered adhesion of these cells. Finally, we provide evidence for enhanced autocrine activation of MAPK signalling and the
AP-1 transcription complex. Together, we have identified changes that are likely to drive proliferation and anchorage-independent
growth of ErbB-2- overexpressing cancer cells.
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The receptor tyrosine kinase ErbB-2 (Her-2/Neu) is overexpressed
in 25 – 30% of all human breast cancers, and is associated with a
poor prognosis and an increased likelihood of metastasis (Slamon
et al, 1987). However, despite intensive research efforts, the
biological mechanisms underlying the oncogenicity of ErbB-2 are
still poorly understood. ErbB-2 is a member of the ErbB family of
growth factor receptors comprising EGFR (ErbB-1), ErbB-2, ErbB-
3 and ErbB-4. Exposure of cells to ErbB receptor-specific ligands
results in receptor homodimerisation and/or cross-family hetero-
dimerisation, kinase activation, and self- and crossphosphoryla-
tion of cytoplasmic tyrosine residues. Various adaptor molecules
bind to the phosphorylated receptors, resulting in signal
transduction initiation that ultimately regulates gene transcription
(Yarden and Sliwkowski, 2001). It appears that the relative
expression level of each ErbB family member, as well as ligand
specificity, determines the nature of the dimerisations, and hence
the repertoire of adaptors which bind to the activated receptors.
This in turn determines the specificity and strength of downstream
signalling (Yarden and Sliwkowski, 2001). While ErbB-2 has no
known ligands, it is the preferred heterodimerisation partner of
EGFR, ErbB-3 and ErbB-4 (Graus-Porta et al, 1997). Thus, ErbB-2
overexpression is believed to enhance signalling from these
receptors in response to binding of their specific ligands, but also
independently through forced receptor association.
Although ErbB-2 overexpression alone cannot transform cells
(Ross and Fletcher, 1998), it has highly integrated roles in cellular
signalling that impact on the classic ‘hallmarks’ of cancer
(Hanahan and Weinberg, 2000). Indeed, ErbB-2 overexpression
can provide self-sufficiency in growth signals, enhanced survival,
anchorage-independent growth, and, importantly, promote tissue
invasion and metastasis. An example of the signalling interplay
that exists is the interaction of ErbB family members with
integrins, the major receptors for the extracellular matrix (ECM)
(Eliceiri, 2001). Indeed, growth factor-induced proliferation and
migration are dependent on integrin-mediated adhesion to the
ECM, including the ECM component fibronectin (FN1) (Danen
and Yamada, 2001).
DNA microarrays allow the parallel analysis of thousands of
genes and offer a powerful technology to further our under-
standing of breast cancer. Global gene-expression profiling has
been applied to breast carcinomas for diagnostic and prognostic
purposes, and has been used to compare breast cancer cell lines
(Ross et al, 2000), tumour tissues (Perou et al, 1999), and to
classify breast cancer tissue and cell lines into subgroups
according to oestrogen receptor status (Gruvberger et al, 2001),
physiological variation (Perou et al, 2000), underlying hereditary
mutations (Hedenfalk et al, 2001; van ‘t Veer et al, 2002) and
invasiveness/metastasis (Zajchowski et al, 2001; van ‘t Veer et al,
2002). Microarray technology also offers the ability to investigate
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ychanges in gene expression resulting from the overexpression of
single oncogenes commonly found in breast cancer. Ideally, this
involves comparison of primary breast tumour material and
normal healthy tissue from the same patient. However, this may
not be possible: taking a biopsy of healthy tissue may be ethically
and clinically unsatisfactory; samples may have different propor-
tions of mixed cell types, and, depending on the grade and stage of
the carcinoma, the tumour sample may have secondary mutations
resulting from chromosomal instability, making the results of a
microarray analysis hard to interpret. While cell lines provide a
more genetically homogenous choice than tissues for breast cancer
studies, they should be closely matched and ideally be human
mammary luminal epithelial cells (HMLECs), the cell type from
which the most common form of breast cancer, infiltrating ductal
carcinoma (IDC), arises.
Despite the increasing number of reports using expression
profiling to decipher the molecular mechanisms of cancer, or to
predict clinical outcome or survival, these studies rarely address
the correlation between mRNA and protein expression. Indeed, it
is as yet unknown whether changes observed at the mRNA level are
translated into similar changes at the protein level on a global
scale, or indeed whether such ‘linked’ mRNA and protein changes
are relevant to the onset of cancer. The correlation between mRNA
and protein expression may be very low over the entire genome
due to the effects of differential mRNA stability gene-specific
regulation of translation, mRNA silencing and differential protein
stability. However, parallel proteomic and microarray comparisons
are still extremely useful if a cell’s response to a given stimuli or
oncogenic conversion are to be properly deciphered. Such
comparisons offer the potential to understand the nature of
deregulated gene expression that leads to cancer progression.
Here we describe the results of a microarray analysis that profiles
the transcriptional responses to ErbB-2 overexpression in a model
HMLEC system, HB4a and C3.6 (Harris et al, 1999). This model is
ideal for the microarray analysis of the effect of ErbB-2 on gene
expression in breast cancer progression, as it consists of the cell
type from which IDCs of the breast arise, has an ErbB-2 expression
level comparable to that seen in carcinomas, and is comprised of a
closely matched test and reference sample. Using this model cell
system and stimulation with heregulin b1 (HRGb1), we have
specifically investigated the transcriptional changes that occur
downstream of ErbB-2/3 heterodimerisation and signalling. More-
over, we have correlated some of the observed mRNA changes with
changes at the protein level in a parallel proteomics study, and
related some of these changes to the transformed characteristics of
these cell lines, specifically enhanced autocrine signalling, prolif-
eration/cell cycle progression and cellular adhesion.
MATERIALS AND METHODS
Cell lines, tissue culture, mitogen stimulation and RNA
extraction
Generation of the parental HB4a mammary luminal epithelial cell
line and derivatives overexpressing ErbB2 (C3.6 and C5.2) has
been described previously (Harris et al, 1999). Cells were cultured
in RPMI-1640 media with 10% (v/v) foetal calf serum (FCS), 2mM
glutamine, 100IUml
 1 penicillin, 100mgml
 1 streptomycin,
5mgml
 1 hydrocortisone and 5mgml
 1 insulin (both Sigma,
Poole, UK) at 371C in a 10% CO2-humidified incubator. The
luminal epithelial cell line Lum878 was maintained under the same
growth conditions and derived from normal human mammary
luminal epithelial cells by immortalisation with SV40 large T
antigen and human telomerase reverse transcriptase (from Dr
Michael O’Hare, Ludwig Institute for Cancer Research). The breast
tumour cell lines BT474, MCF-7, SKBr3, MDA-MB-361, MB-435
and MB-453 were obtained from the American Type Culture
Collection (ATCC), and maintained under culture conditions listed
on the ATCC website (http://www.atcc.org/SearchCatalogs/
Search.cfm). Cell lines SUM159 and SUM185 were from The
University of Michigan Breast Cell/Tissue Bank (from Dr Stephen
Ethier). Details of these cell lines and culture conditions are found
on the SUM-breast cell line web page (http://www.cancer.med.u-
mich.edu/breast_cell/clines/clines.html). For stimulation experi-
ments, HB4a and C3.6 cells at 50 – 60% confluency were starved
for 48h in RPMI-1640 media with 0.1% FCS, 2mM glutamine,
100IUml
 1 penicillin, 100mgml
 1 streptomycin and 5mgml
 1
hydrocortisone (serum-starvation media). Cells were then stimu-
lated by the addition of 1nM HRGb1 (R&D Systems) for 1, 4, 8, 12,
18 and 24h. Four replicate plates of cells were stimulated for each
timepoint. Total RNA was isolated from each replicate experiment
using TRIZOLt Reagent (Life Technologies Inc., Gaithersburg,
MD, USA), according to the manufacturer’s instructions.
Microarray experiments
Microarray analyses were performed on RNA from each of the four
replicate experiments. A ‘reciprocal duplicate’ labelling strategy was
used to minimize the effects of dye bias and to provide statistical
confidence; two hybridisations were performed with the HB4a
sample labelled with Cy3 and the C3.6 sample labelled with Cy5
(duplicates), and two hybridisations were performed with the
labelling reversed (reciprocal duplicates). Hver1.2.1 microarrays
were obtained from The Wellcome Trust Sanger Institute. Probes
consist of a redundant group of 9932 PCR-derived, sequence-verified
cDNA features (representing B6000 unique genes) spotted onto
amine-binding glass slides (details available on The Wellcome Trust
Sanger Institute Microarray Facility homepage (http://www.sanger.-
ac.uk/Projects/Microarrays/)). Protocol 5 from the Facility home-
page was used for generation of fluorescently labelled cDNA targets
using direct Cy dye incorporation. Briefly, 25mgo fR N Aw a su s e dt o
produce labelled cDNA by anchored oligo(dT)-primed reverse
transcription with Superscript II Reverse Transcriptase (Life
Technologies), in the presence of Cy3- or Cy5-dUTP (Amersham,
Chalfont, St Giles, UK). Unincorporated dye was removed using
Autosequ-50 Columns (Amersham, Chalfont, St Giles, UK) and
repetitive DNA sequences were blocked with 8mgC o t 1( R o c h e
Diagnostic Ltd, Lewes, UK) and 8mg poly(dA) (Sigma) DNA before
hybridisation at 471C overnight.
Data analysis and mining
Microarrays were scanned using a ScanArray 4000XL (Packard
BioChip Technology, Billerica, MA, USA) according to the
manufacturer. The raw image data were acquired using ScanArray
v3.0 software, and then exported to QuantArray v3.0 software for
data extraction. Features and background areas were defined using
QuantArray’s Histogram method, and the median intensity for
each channel was used to scale dye-emission signals. Features
visibly affected by hybridisation artefacts were manually flagged
for exclusion. Background subtracted signal intensities of the Cy3
and Cy5 channels for each feature were then loaded into
GeneSpring v4.2 (Silicon Genetics, Redwood City, CA, USA) for
normalisation. The expression level of each probe was derived by
dividing the fluorescence intensity of the C3.6 result by the HB4a
result for each probe in the four replicates. Intensity-dependent
normalisation was applied, where the ratio was reduced to the
residual of the Lowess fit of the intensity vs ratio curve (refer to
GeneSpring v4.2 documentation for more information). When the
control channel value was below 10.0, the data point was
considered bad. The final ratio is the geometric mean of the four
replicates. Expression differences were considered significant if the
ratio of C3.6:HB4a was 0.5 (downregulated), or X2.0 (upregu-
lated). Probes were annotated with an Ensembl Description and ID
(from Ensembl (http://www.ensembl.org/Homo_sapiens/) Release
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on classifications from the Gene Ontologyt Consortium (Ashbur-
ner et al, 2000) and literature reviews.
Differential protein expression
Differential protein expression data were taken from a 2D-
difference gel electrophoresis (2D-DIGE) analysis comparing the
proteomes of serum-starved HB4a and C3.6. cells (Gharbi et al,
2002). This global proteomic analysis provided statistically
significant (Po0.05) expression differences (as average ratios)
for 16 proteins that were present on the microarray. The
expression of a further 27 proteins was compared in serum-
starved HMLECs by immunoblotting with specific antibodies,
using enhanced chemiluminescence for detection, and densitome-
try for quantification (QuantityOne, BioRad). At least three
replicate blots were scanned and quantified for each protein, and
the average ratio of C3.6 vs HB4a was determined.
Cell-adhesion assays
Cells were trypsinised, washed twice in serum-free media and
seeded into 96-well plates (5 10
3cellswell
 1) in either serum-free
media, or serum-free media plus 1nM HRGb1. Wells were either
untreated (adhesion to plastic), or coated with human plasma FN
(Sigma) (adhesion to FN). Cells were allowed to adhere for 1h at
371C, and then washed with PBS. A volume of 50ml of 1mg/ml
 1 3-
[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyl-tetrazolium bromide
(MTT) (Sigma) in serum-free media was added, and cells were
further incubated for 4h. DMSO (100ml) was added, the plates
were shaken for 20min at 221C, and the absorbance read at
540nm. The values given are the average of eight replicate
readings.
Media-swap experiment
Conditioned media (CM) was generated by growth factor
treatment of serum-starved HB4a and C3.6 cells (EGF – 1nM or
Hrgb1–1 n M) for 4h, followed by extensive washing and
replacement with serum-free media for a further 4h. The
conditioned media was used to stimulate serum-starved HB4a
and C3.6 cells for 15min. Mitogenic signalling was monitored by
immunoblotting with phosphospecific antibodies to ERK1/2. To
test for ErbB-specific signalling, CM media was added to serum-
starved cells that had been pretreated with 5mM AG-1478 (a potent
ErbB-kinase inhibitor) for 30min.
RESULTS
Global changes in gene expression
To specifically identify ErbB-2-dependent mRNA changes, ErbB-2-
overexpressing C3.6 cells and their normal parental counterparts
HB4a were serum-starved and stimulated with the mitogen HRGb1
for different times prior to RNA extraction and microarray
analysis of relative mRNA levels. In these experiments, the two
cell lines were directly compared against one another at each
timepoint by cohybridising labelled cDNA from both cell types
onto the same array. Heregulin b1 stimulation would be expected
to signal almost exclusively via ErbB-2/3 heterodimers, given the
propensity of ErbB-3 to heterodimerise preferentially with ErbB-2,
the inability of HRGb1 to stimulate EGFR/ErbB-2 heterodimers
(Yarden and Sliwkowski, 2001) and the absence of ErbB-4 in these
cells (Harris et al, 1999; Timms et al, 2002).
Of the 9932 probes present on the microarray, 667 probes
displayed a greater than two-fold difference in expression between
C3.6 and HB4a cells at one or more of the timepoints. The numbers
of genes with differential expression did not differ substantially
between T1 and T12, but there were significant differences at T0,
T18 and T24 (Figure 1). These variations may reflect the fact that
the C3.6 cells display a greater degree of growth-factor indepen-
dence than the parental cells, and an increased proliferative
capacity, progressing through the cell cycle more rapidly in
response to mitogenic stimulation, as previously reported (Timms
et al, 2002).
Genes that are constitutively higher or lower (i.e. at all
timepoints) in C3.6 vs HB4a cells are expected to have an
expression directly affected by ErbB-2 overexpression, and may
not be related to mitogen stimulation per se. There were 21 such
genes upregulated (including ErbB-2) and 27 genes downregulated
(Figure 1 and Table 1). When classified into groups based on
functional ontology, approximately one-third of the upregulated
genes were found to be involved in cellular metabolic processes.
For example, carbamoylphosphate synthetase 1 (CPS1), the most
highly expressed gene in the data series, is part of the
mitochondrial urea cycle. While differential expression of meta-
bolic enzymes has been reported in breast cancer (Hennipman
et al, 1988), it is possible that this upregulation occurs as a
secondary consequence of the increased energy requirements of
hyperproliferating cells, rather than of a transformed phenotype
(Guppy et al, 2002).
Several of the upregulated genes are reported to have increased
expression in breast cancer. These include: the calcium-binding
protein S100P (Guerreiro Da Silva et al, 2000); the structural
protein L-plastin (LCP1) (Lin et al, 1988) and the intermediate
filament protein vimentin, the upregulation of which has been
correlated with increased invasiveness (Zajchowski et al, 2001).
However, the constitutive upregulation of the cell cycle regulator
cyclin D2 (CCND2) is a novel finding, and of particular interest,
given that ErbB-2 overexpression increases cyclin-dependent
kinase (cdk) activity in these cells (Timms et al, 2002). Notably,
of the 27 constitutively downregulated genes, seven are interferon-
(IFN) inducible (indicated with an asterisk in Table 1). Of these,
the downregulation of the transcriptional regulator ISGF3 gamma
subunit (ISGF3G) has significant implications. ISGF3G, together
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Figure 1 Analysis of global differences in mRNA expression between
C3.6 and HB4a HMLECs. Total number of genes with mRNA ratios
(C3.6:HB4a) with a geometric mean of 2.0 or 0.5 in serum-starved cells
(0), and in cells at six different times (1, 4, 8, 12, 18, and 24h) after HRGb1
treatment. The hashed area represents 20 genes that are upregulated in
C3.6 cells, the gray area, down regulated genes, black and white areas, up
and down regulated genes at all time point, respectively.
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ywith signal transducer and activator of transcription 1 (STAT1)
and STAT2, forms the ISGF3 transcription complex, which is
required for transcription of IFNa/b-inducible genes, including
IFNb itself (Nakaya et al, 2001). Thus, decreased ISGF3G
expression in the C3.6 cells may cause the lowered transcription
of the other IFN-inducible genes.
A number of constitutively downregulated genes have reported
roles in cellular adhesion processes. These include: fibronectin 1
(FN1), a major ECM component required for integrin-mediated
signalling (reviewed in Danen and Yamada, 2001); fibulin 2
(FBLN2), which colocalises with FN1 in vivo (Gu et al, 2000); and
the tissue inhibitor of metalloproteinase 3 (TIMP 3), which is
involved in regulating FN1 degradation (Fata et al, 2001). Given
these changes, it is possible that ErbB-2 overexpression may alter
the adhesive properties of these cells (see below).
Protein expression correlates with gene expression
In order to ascertain whether the observed changes in gene
expression translate into similar changes in protein expression, we
carried out a comparison of mRNA and protein expression.
Protein data were taken from a parallel proteomics study of serum-
starved HB4a and C3.6 cells using two-dimensional difference gel
electrophoresis (2D-DIGE), and from the quantitation of multiple
immunoblotting experiments. The 2D-DIGE analysis identified 30
proteins that were significantly up- or downregulated in response
to ErbB-2 overexpression (Gharbi et al (2002) and unpublished
Table 1 Genes that are constitutively: (a) two-fold upregulated, and (b) two-fold downregulated in C3.6 cells relative to HB4a cells (i.e. under serum-
starved conditions and at all timepoints after stimulation with 1nM HRGb1).
Abbrev Ensembl Number and description Function
Constitutively upregulated
S100P ENSG00000163993 S-100P PROTEIN CA binding
CPS1 ENSG00000021826 CARBAMOYLPHOSPHATE SYNTHASE Metabolism
HIBCH ENSG00000115404 3-HYDROXYISOBUTYRYL-COENZYME A HYDROLASE Metabolism
C20orf16 ENSG00000088826 POLYAMINE OXIDASE ISOFORM-3 Metabolism
ENSG00000162424 SUCCINATE DEHYDROGENASE Metabolism
ENSG00000130021 GS1 PROTEIN Metabolism
FDX1 ENSG00000137714 ADRENODOXIN, MITOCHONDRIAL PRECURSOR Metabolism
COX6C ENSG00000164919 CYTOCHROME C OXIDASE POLYPEPTIDE VIC PRECURSOR Metabolism
CCND2 ENSG00000118971 G1/S-SPECIFIC CYCLIN D2 Proliferation
ENSG00000151465 PROTEIN D123 Proliferation
UCHL1 ENSG00000154277 UBIQUITIN CARBOXYL-TERMINAL HYDROLASE ISOZYME L1 PROTEIN Processing
ERBB2 ENSG00000141736 RECEPTOR PROTEIN-TYROSINE KINASE ERBB-2 PRECURSOR Signalling
LCP1 ENSG00000136167 L-PLASTIN (LYMPHOCYTE CYTOSOLIC PROTEIN 1) Structural protein
VIM ENSG00000026025 VIMENTIN Structural protein
KLF12 ENSG00000118922 KRUEPPEL-LIKE FACTOR 12 Transcription
TRIM29 ENSG00000137699 ATAXIA-TELANGIECTASIA GROUP D-ASSOCIATED PROTEIN Transcription
CPNE3 ENSG00000085719 COPINE III Transport
SSFA2 ENSG00000138434 SPERM-SPECIFIC ANTIGEN 2 Unknown
ENSG00000110696 SMALL ACIDIC PROTEIN Unknown
ENSG00000077232 CDNA FLJ14741 FIS, CLONE NT2RP3002628 Unknown
UNIDENTIFIED TRANSCRIPT Unknown
Constitutively downregulated
SPARC ENSG00000113140 SPARC PRECURSOR Ca binding
IFITM1 ENSG00000142089 INTERFERON-INDUCED TRANSMEMBRANE PROTEIN 1 Immune response*
WNT5A ENSG00000114251 WNT-5A PROTEIN PRECURSOR Ligand
TYMS ENSG00000080868 THYMIDYLATE SYNTHASE Metabolism
OAS1 ENSG00000089127 2’-5’-OLIGOADENYLATE SYNTHETASE 1 Metabolism*
PAPSS2 ENSG00000148615 3’-PHOSPHOADENOSINE 50-PHOSPHOSULFATE SYNTHETHASE 2 Metabolism
CYBA ENSG00000051523 CYTOCHROME B-245 LIGHT CHAIN Metabolism
FTHFD ENSG00000144908 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE Metabolism
ENSG00000133700 INTERFERON INDUCED TRANSMEMBRANE PROTEIN Proliferation
*
ENSG00000137440 HEPARIN BINDING PROTEIN PRECURSOR Proliferation
ENSG00000162569 UBIQUITIN CROSS-REACTIVE PROTEIN PRECURSOR Protein Processing
*
KLK8 ENSG00000160327 NEUROPSIN PRECURSOR Protein Processing
TIMP3 ENSG00000100234 METALLOPROTEINASE INHIBITOR 3 PRECURSOR (TIMP-3) Protein Processing
TRIP12 ENSG00000153827 THYROID RECEPTOR INTERACTING PROTEIN 12 Protein Processing
SERPINH1 ENSG00000149257 47 KDA HEAT SHOCK PROTEIN PRECURSOR Protein Processing
PRSS11 ENSG00000166033 SERINE PROTEASE HTRA1 PRECURSOR Protein Processing
WFDC2 ENSG00000101443 MAJOR EPIDIDYMIS-SPECIFIC PROTEIN E4 PRECURSOR (HE4) Protein Processing
C1S ENSG00000126750 PRECURSOR EC 3.4.21.- SERINE PROTEASE Protein Processing
IGFBP3 ENSG00000146674 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 PRECURSOR Signalling
*
ENSG00000101608 MYOSIN REGULATORY LIGHT CHAIN 2, NONSARCOMERIC Structural Protein
FN1 ENSG00000115414 FIBRONECTIN PRECURSOR (FN) Structural Protein
FBLN2 ENSG00000163520 FIBULIN-2 PRECURSOR Structural Protein
ISGF3G ENSG00000100915 TRANSCRIPTIONAL REGULATOR ISGF3 GAMMA SUBUNIT Transcription
*
KDELR2 ENSG00000136240 ER LUMEN PROTEIN RETAINING RECEPTOR 2 Transport
ENSG00000136193 Unknown
IFIT1 ENSG00000152777 IFN-INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEATS 1 Unknown
*
Functional classifications (‘Function’) were subjectively given, based on classifications from the Gene Ontologyt Consortium (Ashburner et al, 2000), and literature reviews. IFN-
inducible genes are denoted with an asterisk.
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ydata). Five upregulated proteins that were represented on the
microarrays were also found to be constitutively upregulated in the
mRNA analysis. These were: CPS1, LCP1, the metabolic enzyme 3-
hydroxyisobutyryl coenzyme A hydrolase (HIBCH), copine III,
which may be involved in membrane trafficking (Creutz et al,
1998) and ubiquitin C-terminal hydrolase isozyme L1 (UCHL1), a
deubiquitinating enzyme whose overexpression has been asso-
ciated with progression of non-small-cell lung cancers (Hibi et al,
1999) and colon cancer invasiveness (Yamazaki et al, 2002). The
ERM protein radixin (RDX) was also found to be upregulated by
2D-DIGE analysis, but fell just below the two-fold cutoff used in
the microarray analysis. The upregulation of several of these gene
products, including CCND2, was further confirmed by immuno-
blotting (Figure 2A). Notably, protein levels were also increased in
another HMLEC clone (C5.2), which expresses even higher levels
of ErbB-2. These genes thus appear to be both transcriptionally
and translationally upregulated in response to ErbB-2 over-
expression.
We further tested the relationship between ErbB-2 expression
and the expression of UCHL1, CPS1 and copine III in a panel of
breast cancer cell lines. UCHL1 (Figure 2A, right-hand panel) was
restricted to luminal epithelial cells (HB4a, C3.6, C5.2 and
Lum878), and was not detected in any of the breast tumour cell
lines which do not display a luminal epithelial cell morphology.
CPS1 protein expression was also restricted to luminal cells,
although it was also detected in BT474, which expresses high levels
of ErbB-2 and ErbB-3 (Figure 2B). Copine III was expressed in all
cell lines, and its expression correlated with both ErbB-3 and ErbB-
2 overexpression. In agreement with the microarray analysis, four
IFN-inducible genes (ISGF3G, MnSOD and the IFN-regulated viral
resistance GTP-binding proteins MxA and MxB) were shown to be
significantly downregulated at the protein level (Figure 2B and C).
Moreover, expression of ISGF3G and MxA was inversely correlated
with ErbB-2 expression in the panel of breast tumour cell lines
(Figure 2B). To further examine the regulation of these genes,
serum-starved cells were treated with EGF, HRGb1, IFNg, or IFNb,
and expression levels determined by immunoblotting (Figure 2C).
While the ErbB receptor ligands had no effect on expression, IFNg
treatment resulted in the induction of ISGF3G and MnSOD in the
C3.6 cells, and IFNb treatment induced the expression of all four
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Figure 2 Validation of differential gene expression at the protein level. (A) Upregulation of ErbB-2, carbamoyl phosphate synthetase 1 (CPS1I), copine III,
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treatment, the basal levels of these IFN-inducible genes are
suppressed in response to ErbB-2 overexpression.
An overall comparison of the protein and mRNA ratios for 43
genes showed a statistically significant and high correlation co-
efficient of 0.81 (po0.001), and a moderate linear regression (R
2)
of 0.66 (Po0.001) (Figure 2D). Thus, altered mRNA expression
correlates strongly and positively with increased translation and
protein expression. The moderate R
2 value, however, indicates that
mRNA level cannot necessarily be used to predict a gene’s protein
level. To our knowledge, this is the highest correlation between
protein and mRNA ratios observed in cells from a higher
organism, although we speculate that ErbB-2 overexpression must
direct the differential translational regulation and/or protein
stability of some genes, rather than their transcription alone. For
example, such post-transcriptional regulation would explain the
modulated expression of EGFR and YWHAB (Figure 2D), for
which mRNA and protein levels do not correlate.
Genes differentially expressed in response to growth factor
treatment
We next examined the genes that were differentially expressed in
response to HRGb1 stimulation. For brevity, the genes are listed in
Tables S2-S5 of Supplementary Data, and we only focus here on
several interesting groups that may have an impact on ErbB-2-
dependent cellular phenotypes. Of the downregulated genes,
cyclin-dependent kinase inhibitor 3 (CDKN3), growth arrest and
DNA-damage-inducible a (GADD45A) and CDKN2C/p18 are
known to be cdk inhibitors (Gyuris et al, 1993; Guan et al, 1994;
Jin et al, 2000). Their downregulation thus correlates with the
observed hyperactivity of cdk6 and cdk2 in the C3.6 cells, as
previously reported (Timms et al, 2002), and suggests one
mechanism by which ErbB-2 can promote proliferation through
enhanced cell cycle progression.
Notably, additional IFN-inducible genes were also downregu-
lated in the C3.6 cells in a HRGb1-dependent manner (S3B and
S5B). These include MxB, IFN-regulatory factor 3 (IRF3), IRF7,
HLA I a-chain, death-associated protein kinase 1, tryptophanyl-
tRNA synthetase and retinoic acid and IFN-inducible 58kDa
protein. The ISGF3 complex component STAT1 was also down-
regulated at T18, while the suppressor of cytokine signalling-2
(SOCS-2), a STAT-induced STAT inhibitor (Krebs and Hilton,
2000), was upregulated. These data again support the notion that
ErbB-2 overexpression can suppress IFN signalling to down-
regulate the expression of IFN-inducible genes.
ErbB-2-dependent modification of HMLEC adhesion
A significant number of ECM components or genes involved in
ECM modelling, degradation and cell adhesion were also found to
be differentially expressed following HRGb1 treatment. These
include the ECM components fibulin 1 and collagens a1(I) and
a1(VIII), the integrin subunits a1, a2, b4 and aV, the proteases
cathepsins H and L and matrilysin (MMP7), the protease inhibitor
TIMP2, the b-galactoside-binding proteins galectins 2 ,7 and 9 and
uPAR, the receptor for urokinase plasminogen activator, a serine
protease that has been linked to breast cancer through its
association with integrins (van der Pluijm et al, 2001). Given that
we also observed the constitutive downregulation of other genes
involved in cellular adhesion (Table 1), we tested the hypothesis
that ErbB-2 reduces adhesion and that this can be modulated by
HRGb1 stimulation. Adhesion assays were thus performed under
serum-starved conditions and 1h after HRGb1 treatment
(Figure 3). Since the integral ECM component FN1 is constitutively
downregulated in C3.6 cells, adhesion was also tested on FN-coated
plastic. We found that serum-starved C3.6 cells were significantly
less adhesive than HB4a cells on plastic, although their adhesion
was increased on FN-coated plastic, or when cells were treated with
HRGb1 (Figure 3). Moreover, attachment to FN in the presence of
HRGb1 resulted in a similar level of adhesion for both cell types.
These data show that the ErbB-2-dependent expression of these
genes does indeed translate to a phenotype of decreased adhesion,
which can be partially rescued by FN restoration, or HRGb1sti-
mulation, and rescued fully by both treatments.
Differential regulation of autocrine/paracrine signalling by
ErbB-2
The microarray analysis also identified a number of differentially
regulated genes involved in autocrine and paracrine responses in
breast cancer. These include: amphiregulin (AREG), an autocrine
growth factor ligand of EGFR; glypican-1 precursor (GPC1), a
modulator of the mitogenic activities of ErbB receptor ligands such
as HRGb1 and AREG, and frequently upregulated in breast cancer
(Matsuda et al, 2001); parathyroid hormone-related protein
precursor (PTHLH), a signaller of bone remodelling found
overexpressed in bone-metastasised breast cancers (Iddon et al,
1999); endothelin-2 (EDN2), stanniocalcin 1 (STC1); adrenome-
dullin precursor (ADM) and secretory granule proteoglycan core
protein (PRG1). Of all the genes in the analysis, AREG expression
was the most variable across the time course; five-fold down-
regulated at T0, equivalent expression at T1, two-fold down at T4-
12, two-fold up at T18, and two-fold down at T24 (Figure 4A).
These data are indicative of a differential autocrine response
following HRGb1 stimulation.
To confirm the autocrine secretion of mitogenic ligands, serum-
starved HB4a and C3.6 cells were treated with conditioned media
(CM) from serum-starved (Ctrl), EGF-, or HRGb1-treated cells,
and activation of MAPK signalling monitored after 15min by
immunoblotting with a phosphospecific antibody (Figure 4B). This
showed that CM from both cell types could trigger MAPK
signalling (ERK1/2 activation), with C3.6 CM producing a higher
level of activation. Moreover, pretreatment of cells with a potent
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Figure 3 Cell adhesion assays on C3.6 and HB4a in serum-free media,
or media supplemented with 1mM HRGb1 as measured by incorporation
of MTT into living cells (A540nm). Adhesion onto plastic or fibronectin-
coated plates was measured after 1h. Results are the average of eight
replicates, and error bars represent the standard deviation.
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response (Figure 4B, lanes labelled þAG), supporting the notion
that ligands such as AREG are secreted in response to growth
factor treatment and can activate autocrine mitogenic signalling
through the ErbB receptor system.
Notably, a conspicuous number of downstream mediators of
MAPK signalling were also upregulated in the C3.6 cells in to
response short-term HRGb1 treatment (T1) and again at later
timepoints. These genes include components of the AP-1
transcription complex (c-FOS, FOS-B, FOS-related antigen 1,
JUN-B (Figure 4C)), the transcription factor c-ETS-2 and the
orphan nuclear receptor HMR (Table S4A). This apparent biphasic
regulation is suggestive of two waves of transcription as cells
respond to HRGb1, and their increased expression consistent with
a higher mitogenic signalling capacity that correlates with
hyperactivation of MAPK signalling, as previously observed in
the ErbB-2-overexpressing cells (Timms et al, 2002).
DISCUSSION
The identification of genes that are differentially expressed in
ErbB-2-dependent breast cancer is an important step in elucidat-
ing the mechanisms of tumorigenesis. To this end, we carried out a
parallel microarray and proteomic analysis to investigate ErbB-2-
and HRGb1-dependent changes in gene expression in a relevant
model cell system of breast cancer. This study also addresses
whether the differential expression of genes could be involved in
generating ErbB-2-dependent cellular phenotypes such as hyper-
proliferation, mitogen- and anchorage-independent growth.
We firstly report that the correlation between mRNA and
protein expression for a subset of 43 genes was very high (0.81) in
these cells. This conflicts somewhat with previous reports using
human liver (Anderson and Seilhamer, 1997), lung adenocarcino-
mas (Chen et al, 2002) and S. cerevisiae (Gygi et al, 1999), where
lower correlations were observed. This discrepancy may be due to
the different cell types used, the different methods of mRNA and
protein quantitation used, and/or the subset of genes used for the
comparisons. However, the comparison performed here not only
helps to validate the findings of the microarray analysis, but also
points to the mode of regulation of these differentially regulated
genes. Thus, while it appears that the expression of the majority of
genes is controlled at the level of transcription in response to
ErbB-2 overexpression, a significant minority (B33%) are
regulated post-transcriptionally, in agreement with the reports
mentioned above.
Among the genes and proteins shown to display altered
expression, six functional groups were identified: genes with roles
in cellular metabolism, regulation of cell cycle progression, IFN
signalling, cell adhesion, autocrine/paracrine signalling and AP-1-
mediated transcription. Interestingly, several of the constitutively
deregulated genes identified (S100P, LCP1, vimentin, IGFBP3 and
FN1) have been associated with breast tumorigenesis in other
studies. This finding not only validates the model cell system used
here, but also supports the usefulness of these genes as markers of
breast cancer progression. A recent study by Mackay et al., 2003
also reported microarray analysis of genes associated with ErbB-2
expression in the HB4a, C3.6, C5.2 model system. The same
microarrays were employed as in our study, and 61 genes were
reported as significantly up- or downregulated. Consequently, a
number of differentially expressed genes identified in the two
studies are the same: S100P, CPS1, vimentin (constitutively
upregulated), IGFBP3, FN1, SPARC (constitutively downregulated)
and 12 other genes found to be differentially expressed at one or
more timepoints, or from the protein analysis. This consistency
supports the identification of these genes as bona fide targets of
ErbB-2 overexpression. However, there were several novel gene
expression changes that were unique to our study (e.g. CCND2,
ISGF3G, UCHL1, LCP1 and CPNE3), and that positively correlated
with proteomic changes. The divergence between the two studies is
likely to reflect differential data extraction as a result of differential
hybridisation, hybridisation artefacts and signal-to-noise ratios
across chips and between experiments, but may also reflect the fact
that cells were cultured under different conditions.
Our previous study using this cell system demonstrated that
enhanced MAPK activation in the ErbB-2-overexpressing cells
played a critical role in cell cycle progression and proliferation by
promoting cdk6 and cdk2 activity (Timms et al, 2002). This was
due to a combination of increased cyclin D1 and cdk6 protein
expression, and a reduction in the expression level and binding of
the cdk inhibitor p27 to cdk2. The present study identifies
additional potential effectors of ErbB-2-dependent cell cycle
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Figure 4 Expression of an autocrine growth factor and components of
the AP-1 transcription complex. (A) Expression profile (C3.6:HB4a) of
amphiregulin precursor (AREG) across the timecourse of HRGb1
stimulation: (B) Treatment of serum-starved cells with conditioned media
from EGF or HRGb1-stimulated cells results in an ErbB-dependent
activation of MAPK signalling. Conditioned media (CM) were generated
as described in Materials and Methods, and used to stimulate serum-
starved and AG-1478-treated HB4a and C3.6 cells for 15min. MAPK
activation was monitored by immunoblotting with antibodies recognising
the phosphorylated/activated forms of ERK1 and 2. Blots were reprobed
with anti-ERK antibodies to check protein levels. (C) HRGb1-induced
expression profile of Fos and Jun family members (components of the AP-1
transcription complex) in C3.6 vs HB4a cells.
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cdk inhibitors and the constitutive upregulation of CCND2 (cyclin
D2). Although cyclins are generally considered as positive
mediators of mitogen-induced cell cycle progression, it has been
shown that loss of CCND2 expression occurs in primary breast
tumours (Evron et al, 2001). Despite this, expression of CCND2
can reduce the dependence on serum for proliferation of breast
epithelial cells, and promote cell cycle progression through
activation of cdk2 (Sweeney et al, 1997). Thus, a combination of
factors appears to drive ErbB-2-dependent cell cycle progression
and hence tumorigenic potential in ErbB-2-overexpressing luminal
epithelial cells.
A novel and surprising result of this study was the down-
regulation of multiple IFN-inducible genes in the ErbB-2-over-
expressing cells. This downregulation was shown at both the
protein level (ISGF3, MxA, MxB and MnSOD) as well as the mRNA
level (seven constitutive and a further seven HRGb1-dependent
genes), and there was a strong inverse correlation between ErbB-2
expression and ISGF3G expression in the panel of breast tumour
cell lines used. Since IFN stimulation produced a robust induction
of several of these genes (Figure 2), these data imply that ErbB-2
overexpression basally represses IFN signalling in the absence of
IFNs. The ISGF3G subunit is a critical component of the ISGF3
transcriptional activator complex for many IFN-inducible genes
(Bluyssen et al, 1996). We propose that its downregulation could
produce the observed suppression of other IFN-inducible genes.
IFNs are antiproliferative and can promote apoptosis under certain
conditions (reviewed in Stark et al, 1998), so the reduced
expression of these genes is likely to contribute to the increased
proliferative capacity of C3.6 cells. The observed constitutive
downregulation of insulin-like growth factor-binding protein 3
(IGFBP3) is also interesting in this context. As well as regulating
the circulating levels of IGFs to suppress proliferation, it has been
proposed that IFNg’s antiproliferative effect is mediated through
IGFBP3 (Katz et al, 1999). The modulation of IFN signalling in
ErbB-2-overexpressing breast cancers warrants further investiga-
tion, and may possibly identify new therapy targets, and/or allow
optimisation of current therapies that utilise IFNs to treat patients
with cancer (Tossing, 2001).
A significant number of the differentially regulated genes are
known modulators of ECM modelling and cellular adhesion.
Specifically, FN1, TIMP3 and FBLN2 were all constitutively
downregulated, changes which are likely to affect integrin-
mediated cellular adhesion. In support of this, we showed that,
under serum-starved conditions, the C3.6 cells were less adherent,
consistent with ErbB-2 promoting anchorage-independent growth
(Harris et al, 1999). The apparent rescue of this adhesion
phenotype by plating onto fibronectin (Figure 3) substantiates
the notion that ErbB-2 suppression of FN1 plays a functional role
in anchorage-independent growth and metastasis, as reported
previously (Werbajh et al, 1998; Ignatoski et al, 2000). While our
data also suggested that HRGb1 can modify adhesion, and hence
the potential for invasiveness, the mechanistic details of this
modification are unclear and require further detailed investigation.
Finally, the temporal differential expression of AP-1 transcrip-
tion complex components (Figure 4C) is suggestive of biphasic
transcriptional activity following HRGb1 stimulation. Our hypoth-
esis is that an immediate-early wave of transcription is induced by
HRGb1, and that a secondary wave of transcription, mediated via
the MAPK pathway, is induced by autocrine/paracrine growth
factor production. In support of this, we saw the upregulation of
numerous autocrine factors, and further showed that conditioned
media from cells treated with either EGF or HRGb1 was able to
activate MAPK signalling when added to serumstarved cells.
Moreover, this activation could be blocked by pretreatment of cells
with an inhibitor of ErbB receptor kinase activity (AG-1478). This
suggests that ErbB-dependent autocrine signalling occurs in these
cells (possibly through production of AREG), a process which may
contribute to enhanced proliferation.
In summary, it appears that ErbB-2 overexpression produces a
combination of increased and temporal MAPK signalling, in-
creased ErbB-related autocrine signalling, increased cdk activity
(via upregulation of cyclin D1 and CCND2, and downregulation of
cdk inhibitors), inhibition of basal IFN signalling and reduced
cellular adhesion. Together, these changes would drive the
anchorage-independent proliferation of HMLECs to promote
tumorigenesis.
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